JP5536336B2 - α−ヘリックス類似体および癌幹細胞の治療に関する方法 - Google Patents

α−ヘリックス類似体および癌幹細胞の治療に関する方法 Download PDF

Info

Publication number
JP5536336B2
JP5536336B2 JP2008540227A JP2008540227A JP5536336B2 JP 5536336 B2 JP5536336 B2 JP 5536336B2 JP 2008540227 A JP2008540227 A JP 2008540227A JP 2008540227 A JP2008540227 A JP 2008540227A JP 5536336 B2 JP5536336 B2 JP 5536336B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
mmol
amino
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008540227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515890A5 (https=
JP2009515890A (ja
Inventor
カーン ミシェル
Original Assignee
チョンウェ ファーマ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チョンウェ ファーマ コーポレイション filed Critical チョンウェ ファーマ コーポレイション
Publication of JP2009515890A publication Critical patent/JP2009515890A/ja
Publication of JP2009515890A5 publication Critical patent/JP2009515890A5/ja
Application granted granted Critical
Publication of JP5536336B2 publication Critical patent/JP5536336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008540227A 2005-11-08 2006-11-08 α−ヘリックス類似体および癌幹細胞の治療に関する方法 Active JP5536336B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73465505P 2005-11-08 2005-11-08
US60/734,655 2005-11-08
PCT/US2006/043859 WO2007056593A2 (en) 2005-11-08 2006-11-08 α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS

Publications (3)

Publication Number Publication Date
JP2009515890A JP2009515890A (ja) 2009-04-16
JP2009515890A5 JP2009515890A5 (https=) 2009-12-24
JP5536336B2 true JP5536336B2 (ja) 2014-07-02

Family

ID=37890190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540227A Active JP5536336B2 (ja) 2005-11-08 2006-11-08 α−ヘリックス類似体および癌幹細胞の治療に関する方法

Country Status (8)

Country Link
US (2) US20070129353A1 (https=)
EP (1) EP1957516B1 (https=)
JP (1) JP5536336B2 (https=)
KR (1) KR101486490B1 (https=)
AU (1) AU2006311433B2 (https=)
CA (1) CA2629136C (https=)
ES (1) ES2570994T3 (https=)
WO (1) WO2007056593A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
WO2007139346A1 (en) * 2006-05-30 2007-12-06 Choongwae Pharma Corporation Composition for induction or inhibition of stem cell differentiation
US20080118518A1 (en) * 2006-09-07 2008-05-22 Cirrito Thomas P Cancer stem cell-targeted cancer therapy
US20100298760A1 (en) * 2007-11-05 2010-11-25 Bernat Olle Methods, kits, and compositions for administering pharmaceutical compounds
JP5530427B2 (ja) 2008-06-06 2014-06-25 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ アルファへリックスミメティック及び関連の方法
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤
US20100022549A1 (en) * 2008-07-23 2010-01-28 The Scripps Research Institute Alpha-helix mimetic with functionalized pyridazine
AU2009286528B2 (en) * 2008-08-29 2014-07-17 Msd Italia S.R.L. Saturated bicyclic heterocyclic derivatives as Smo antagonists
US20100080855A1 (en) * 2008-09-12 2010-04-01 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies
CN102186853A (zh) 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
CA2758904C (en) * 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
EP2427451B1 (en) * 2009-05-07 2019-03-20 PRISM BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
WO2011096440A1 (ja) 2010-02-03 2011-08-11 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 天然変性タンパク質に結合する化合物およびそのスクリーニング方法
EA201291460A1 (ru) 2010-05-28 2013-11-29 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Олигобензамидные соединения и их применение
ES2552462T3 (es) 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012115286A1 (en) 2011-02-25 2012-08-30 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
RU2618871C2 (ru) 2011-06-09 2017-05-11 Ф. Хоффманн-Ля Рош Аг Способ дифференциации плюрипотентных стволовых клеток в клетки сосудистого русла
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
CN105899211A (zh) 2013-10-18 2016-08-24 小路弘行 使用cbp/连环蛋白的抑制剂治疗肝纤维化
EP3150207B1 (en) * 2014-03-28 2019-12-25 National University Corporation Tottori University Inhibitory effect of low molecular weight compound on cancer and fibrosis
MX373231B (es) * 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
EP3841197A1 (en) 2018-08-21 2021-06-30 F. Hoffmann-La Roche AG Methods for assessing transendothelial barrier integrity
EP3867358A1 (en) 2018-10-19 2021-08-25 F. Hoffmann-La Roche AG Synergistic transcription factors to induce high resistance transendothelial barrier
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
WO2022076262A1 (en) 2020-10-05 2022-04-14 Genesis Molecular Technologies, Inc. Topical agents for dermatological applications
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2002092010A2 (en) * 2001-05-16 2002-11-21 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1444235B1 (en) * 2001-10-12 2008-06-11 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7390814B2 (en) * 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
RU2005128497A (ru) 2003-02-13 2006-01-27 Санофи-Авентис Дойчленд Гмбх (De) Замещенные производные гексагидропиразино (1,2-а) пиримидин-4,7-диона, способы их получения и их применение в качестве лекарственных средств
CA2537099A1 (en) 2003-08-28 2005-03-10 Choongwae Pharma Corporation Modulation of .beta.-catenin/tcf activated transcription
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
US7915251B2 (en) * 2005-03-18 2011-03-29 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis

Also Published As

Publication number Publication date
US20070129353A1 (en) 2007-06-07
KR101486490B1 (ko) 2015-01-27
WO2007056593A3 (en) 2007-07-12
AU2006311433B2 (en) 2012-06-28
CA2629136C (en) 2016-03-08
CA2629136A1 (en) 2007-05-18
JP2009515890A (ja) 2009-04-16
US8293743B2 (en) 2012-10-23
ES2570994T3 (es) 2016-05-23
EP1957516B1 (en) 2016-03-09
AU2006311433A1 (en) 2007-05-18
WO2007056593A2 (en) 2007-05-18
US20100069333A1 (en) 2010-03-18
EP1957516A2 (en) 2008-08-20
KR20080070060A (ko) 2008-07-29

Similar Documents

Publication Publication Date Title
JP5536336B2 (ja) α−ヘリックス類似体および癌幹細胞の治療に関する方法
JP6970802B2 (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
KR101258298B1 (ko) 암 및 혈관형성의 이중 소분자 억제제
CN100475816C (zh) 回折模拟物及其相关的方法
KR20090005296A (ko) 뒤시엔느 근이영양증의 치료
KR20150091389A (ko) 글루타미나제의 헤테로사이클릭 억제제에 의한 암 치료
EA019566B1 (ru) Низкомолекулярные ингибиторы mdm2
JP6131272B2 (ja) キナーゼ阻害活性を有するベンズヒドロール−ピラゾール誘導体及びその使用
CZ113692A3 (en) Quinoxalines, process of their preparation and their use
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
Feng et al. Structure-based design and characterization of the highly potent and selective covalent inhibitors targeting the lysine methyltransferases G9a/GLP
EP4153587A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
EP1728790A1 (en) Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
EP3735407B1 (en) Substituted halo-quinoline derivates for use in the treatment of lymphomas and leukemia
EP4441052B1 (en) Compounds
CN107849033A (zh) 用于治疗Rac‑GTP酶介导的病症的化合物
WO2025024377A1 (en) Inhibitors of rna binding protein igf2bp3
WO2025222157A1 (en) Substituted pyrazole and isoxazole derivatives and methods of use thereof
WO2024184316A1 (en) Bifunctional protein targeting chimeras (protacs) comprising arylidene-indolinone scaffold as dcaf11 ligand and use thereof
WO2026012091A1 (zh) 一种雌激素受体蛋白降解靶向嵌合体化合物及其应用
CN120682194A (zh) 一种降解hpk1蛋白的protac化合物及其应用
CN119350313A (zh) 一种特异靶向降解pin1蛋白的化合物及应用
TW201443016A (zh) 具有醯胺－內醯胺之異羥肟酸衍生物作爲有效的組蛋白脫乙醯基酶抑制劑及其醫藥用途
CA3088801A1 (en) Compounds for treating rac-gtpase mediated disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140424

R150 Certificate of patent or registration of utility model

Ref document number: 5536336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250